Navigation Links
Quest Diagnostics Reports Second Quarter 2013 Financial Results
Date:7/18/2013

strategically aligned, accretive acquisitions.  In addition, we continued to refocus on diagnostic information services through our ongoing portfolio review. In the second quarter, we completed the sale of HemoCue, and used the proceeds to repurchase shares. We repurchased $405 million of our shares in the second quarter, bringing year to date share repurchases to $467 million. This morning, we completed the sale of the ibrutinib royalty rights to Royalty Pharma for $485 million in cash. We expect to use the proceeds to drive shareholder value, consistent with our capital deployment strategy."

First Half PerformanceRevenues from continuing operations were $3.6 billion for the first six months of 2013, 4.9% below the prior year. Adjusted income from continuing operations was $307 million, or $1.95 per diluted share, compared to $353 million, or $2.20 per diluted share, in 2012. On a reported basis, income from continuing operations was $268 million, or $1.71 per diluted share, compared to $331 million, or $2.06 per diluted share, in 2012.

Adjusted operating income from continuing operations for the first half of 2013 was $579 million, or 16.1% of revenues, compared to $667 million, or 17.6% of revenues, for 2012. On a reported basis, operating income from continuing operations was $516 million, or 14.3 % of revenues, compared to $631 million, or 16.7% of revenues, in 2012. Cash provided by operations was $255 million, compared to $412 million in the first six months of 2012.

Outlook for 2013 For 2013, the company estimates results from continuing operations, before special items, as follows:

  • Revenues now expected to be 1% to 2% below the prior year, compared to previous guidance approximating the prior year level;
  • Earnings per diluted share now expected to be between $4.35 to $4.50, compared to previous guidance of between $4.35 and $4.55;
  • Cash provided by operations to approach $1 billion, compared to previo
    '/>"/>

  • SOURCE Quest Diagnostics Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
    2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    3. A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled
    4. Survey Reveals Paternity Questions Loom for More Than One in 10 Americans
    5. S.E.D. Labs to be Acquired by Quest Diagnostics
    6. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
    7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
    8. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
    9. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
    10. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
    11. Questcor Pharmaceuticals Expands Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... Md. , Nov. 24, 2014  Spherix ... development company committed to the fostering and monetization ... Spherix v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M ... Case No. 3:13-cv-03496-M, both in the United States ... Texas . On ...
    (Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
    (Date:11/22/2014)... 21, 2014 During his lifetime Richard ... need to surround himself with great people and take ... his friends often marveled at his extraordinarily courageous attitude ... life and -- even with his death impending—that’s how ... disease that would ultimately take his life. , Carrying ...
    (Date:11/22/2014)... (PRWEB) November 21, 2014 CannLabs, ... cloud based analytics and scientific testing methodologies relating to ... for a $750,000 line of credit from an existing ... pleased to have secured this commitment from one of ... Officer of CannLabs. “This capital will help accelerate our ...
    Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2
    ... April 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... research group at St. James,s University Hospital in ... reovirus in the May 1, 2008,online issue of ... "Reovirus,Activates Human Dendritic Cells to Promote Innate Antitumor ...
    ... SectorWatch.biz announces the,availability of MarketStats on ... today within the biotechnology and diagnostic testing ... equities and the,opportunity for investors to respond ... sector., Investors can view SectorWatch.biz MarketStats ...
    ... Company Increases Focus on PMA Study, FORT ... (OTC Bulletin Board: IMDS) announced that on,April 16, ... of its,three outside directors Jay Bendis, Patrick Gorman, ... with a request by outside,funding sources as a ...
    Cached Biology Technology:Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 3Imaging Diagnostic Systems Accepts Resignations of Outside Directors 2Imaging Diagnostic Systems Accepts Resignations of Outside Directors 3
    (Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
    (Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
    (Date:11/6/2014)... when that predator runs so fast that it essentially blinds ... the fastest creature on Earth. Some of these half-inch-long beetles ... miles per hour). The fastest human can do about five ... beetle, a person would have to hit 480 miles per ... peak speeds, everything becomes a blur. They can,t gather enough ...
    Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2The tiger beetle: Too fast to see 2
    ... is launching the first integrated, drug development pipeline ... diseases. The $24 million program jumpstarts a trans-NIH ... Diseases Program, or TRND. , The program, ... TRND creates a drug development pipeline within the ...
    ... rapid growth of institutional Memberships for open access ... of the "Online Reporting System" for its open ... BioMed Central,s cutting edge publishing platform, the new ... and help reduce the administrative costs associated with ...
    ... personal care products (PPCPs) carried in biosolids (i.e., ... groundwater when these materials are applied as fertilizer ... created by land application of liquid municipal biosolids ... macropores may be too short for sorption equilibration ...
    Cached Biology News:NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5Simulating pharmaceutical and personal care product transport 2
    ... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
    ...
    ... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
    ... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Viruses microRNA Microarray ...
    Biology Products: